Hormonal modulators of glial ABCA1 and apoE levels

Journal of Lipid Research

Volumn 54, Issue 11, 2013, Pages 3139-3150

  Fan, Jianjia ^a   Shimizu, Yoko ^b   Chan, Jeniffer ^a   Wilkinson, Anna ^a   Ito, Ayaka ^c   Tontonoz, Peter ^c   Dullaghan, Edie ^b   Galea, Liisa A M ^a   Pfeifer, Tom ^b   Wellington, Cheryl L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b Centre for Drug Research and Development   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apolipoprotein E; Astrocytoma; ATP binding cassette transporter A1; Liver X receptor; Progesterone; Progestin

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; ABC TRANSPORTER A1; APOLIPOPROTEIN E; APOLIPOPROTEIN E3; CHOLESTEROL; GESTAGEN; LYNESTRENOL; PROGESTERONE RECEPTOR;

ANIMAL CELL; ARTICLE; ASTROCYTOMA CELL; BRAIN LEVEL; CELL IMMORTALIZATION; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; EMBRYO; GLIA CELL; HOMEOSTASIS; HUMAN; HUMAN CELL; LIPID ANALYSIS; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UPREGULATION;

APOLIPOPROTEIN E; ASTROCYTOMA; ATP BINDING CASSETTE TRANSPORTER A1; LIVER X RECEPTOR; PROGESTERONE; PROGESTIN;

ANIMALS; APOLIPOPROTEIN A-I; APOLIPOPROTEIN E3; APOLIPOPROTEINS E; ASTROCYTES; ATP BINDING CASSETTE TRANSPORTER 1; BIOLOGICAL TRANSPORT; CELL LINE; CHOLESTEROL; ESTROGENS; HOMEOSTASIS; HORMONES; HUMANS; LYNESTRENOL; MICE; NEUROGLIA; ORPHAN NUCLEAR RECEPTORS; PROGESTERONE; RECEPTORS, PROGESTERONE; RNA, MESSENGER; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; UP-REGULATION;

EID: 84886017984     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M042473     Document Type: Article

References (75)

1. Pitas, R. E., J. K. Boyles, S. H. Lee, D. Foss, and R. W. Mahley. 1987. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta. 917: 148-161. (Pubitemid 17231059)
2. Linton, M. F., R. Gish, S. T. Hubl, E. Butler, C. Esquivel, W. I. Bry, J. K. Boyles, M. R. Wardell, and S. G. Young. 1991. Phenotypes of apoliprotein B and apolipoprotein E after liver transplantation. J. Clin. Invest. 88: 270-281.
3. Ladu, M. J., C. Reardon, L. Van Eldik, A. M. Fagan, G. Bu, D. Holtzmann, and G. S. Getz. 2000. Lipoproteins in the central nervous system. Ann. N. Y. Acad. Sci. 903: 167-175. (Pubitemid 30251555)
4. Vance, J. E., and H. Hayashi. 2010. Formation and function of apolipoprotein E-containing lipoproteins in the nervous system. Biochim. Biophys. Acta. 1801: 806-818.
5. Hirsch-Reinshagen, V., S. Zhou, B. L. Burgess, L. Bernier, S. A. McIsaac, J. Y. Chan, G. H. Tansley, J. S. Cohn, M. R. Hayden, and C. L. Wellington. 2004. Deficiency of ABCA1 impairs apolipoprotein E metabolism in brain. J. Biol. Chem. 279: 41197-41207. (Pubitemid 39287722)
6. Fryer, J. D., R. B. DeMattos, L. M. McCormick, M. A. O'Dell, M. L. Spinner, K. R. Bales, S. M. Paul, P. M. Sullivan, M. Parsadanian, G. Bu, et al. 2005. The low density lipoprotein receptor regulates the level of central nervous system human and murine apolipoprotein E but does not modify amyloid plaque pathology in PDAPP mice. J. Biol. Chem. 280: 25754-25759. (Pubitemid 40962285)
7. Herz, J. 2009. Apolipoprotein E receptors in the nervous system. Curr. Opin. Lipidol. 20: 190-196.
8. Strittmatter, W. J., and A. D. Roses. 1995. Apolipoprotein E and Alzheimer disease. Proc. Natl. Acad. Sci. USA. 92: 4725-4727.
9. Pennacchio, L. A., and E. R. Rubin. 2003. Comparative genomic tools and databasses: providing insights into the human genome. J. Clin. Invest. 111: 1099-1106. (Pubitemid 36519923)
10. Corder, E. H., A. M. Saunders, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, G. W. Small, A. D. Roses, J. L. Haines, and M. A. Pericak-Vance. 1993. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261: 921-923. (Pubitemid 23275809)
11. Poirier, J., J. Davignon, D. Bouthillier, S. Kogan, P. Bertrand, and S. Gauthier. 1993. Apolipoprotein E polymorphism and Alzheimer's disease. Lancet. 342: 697-699. (Pubitemid 23279761)
12. Corder, E. H., A. M. Saunders, N. J. Risch, W. J. Strittmatter, D. E. Schmechel, P. C. Gaskell, J. B. Rimmler, P. A. Locke, P. M. Conneally, K. E. Schmader, et al. 1994. Protective effect of apolipoprotein E type 2 for late onset Alzheimer disease. Nat. Genet. 7: 180-184. (Pubitemid 24174658)
13. Cirrito, J. R., P. C. May, M. A. O'Dell, J. W. Taylor, M. Parsadanian, J. W. Cramer, J. E. Audia, J. S. Nissen, K. R. Bales, S. M. Paul, et al. 2003. In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changed in amyloid-beta metabolism and half-life. J. Neurosci. 23: 8844-8853. (Pubitemid 37210896)
14. Hashimoto, T., A. Serrano-Pozo, Y. Hori, K. W. Adams, S. Takeda, A. O. Banerji, A. Mitani, D. Joyner, D. H. Thyssen, B. J. Bacskai, et al. 2012. Apolipoprotein E, especially apolipoprotein E4, increases the oligomerization of amyloid beta peptide. J. Neurosci. 32: 15181-15192.
15. Wisniewski, T., and B. Frangione. 1992. Apolipoprotein E: a pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci. Lett. 135: 235-238.
16. Strittmatter, W. J., K. H. Weisgraber, D. Y. Huang, L. M. Dong, G. S. Salveson, M. Pericak-Vance, D. Schmechel, A. M. Saunders, D. Goldgaber, and A. D. Roses. 1993. Binding of human apolipoprotein E to synthetic amyloid á peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90: 8098-8102. (Pubitemid 23260862)
17. Michikawa, M., Q. W. Fan, I. Isobe, and K. Yanagisawa. 2000. Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J. Neurochem. 74: 1008-1016. (Pubitemid 30104296)
18. Chen, Y., M. S. Durakoglugil, X. Xian, and J. Herz. 2010. ApoE4 reduces glutamate receptor function and synaptic plasticity by selectively impairing apoE receptor recycling. Proc. Natl. Acad. Sci. USA. 107: 12011-12016.
19. Chen, Y., L. Lomnitski, D. M. Michaelson, and E. Shohami. 1997. Motor and cognitive deficits in apolipoprotein E-deficient mice after closed head injury. Neuroscience. 80: 1255-1262. (Pubitemid 27359807)
20. Han, S. H., and S. Y. Chung. 2000. Marked hippocampal neuronal damage without motor deficits after mild concussive-like brain injury in apolipoprotein E-deficient mice. Ann. N. Y. Acad. Sci. 903: 357-365.
21. Laskowitz, D. T., H. Sheng, R. D. Bart, K. A. Joyner, A. D. Roses, and D. S. Warner. 1997. Apolipoprotein E-deficient mice have increased susceptibility to focal cerebral ischemia. J. Cereb. Blood Flow Metab. 17: 753-758. (Pubitemid 27427579)
22. Lynch, J. R., J. A. Pineda, D. Morgan, L. Zhang, D. S. Warner, H. Benveniste, and D. T. Laskowitz. 2002. Apolipoprotein E affects the central nervous system response to injury and the development of cerebral edema. Ann. Neurol. 51: 113-117. (Pubitemid 34027983)
23. Wahrle, S. E., H. Jiang, M. Parsadanian, J. Legleiter, X. Han, J. D. Fryer, T. Kowalewski, and D. M. Holtzman. 2004. ABCA1 is required for normal CNS apoE levels and for lipidation of astrocyte-secreted apoE. J. Biol. Chem. 279: 40987-40993. (Pubitemid 39287699)
24. Hirsch-Reinshagen, V., L. F. Maia, B. L. Burgess, J. F. Blain, K. E. Naus, S. A. McIsaac, P. F. Parkinson, J. Y. Chan, G. H. Tansley, M. R. Hayden, et al. 2005. The absence of ABCA1 decreases soluble apoE levels but does not diminish amyloid deposition in two murine models of Alzheimer's disease. J. Biol. Chem. 280: 43243-43256. (Pubitemid 43049291)
25. Wahrle, S. E., H. Jiang, M. Parsadanian, R. E. Hartman, K. R. Bales, S. M. Paul, and D. M. Holtzman. 2005. Deletion of Abca1 increases Abeta deposition in the PDAPP transgenic mouse model of Alzheimer disease. J. Biol. Chem. 280: 43236-43242. (Pubitemid 43049290)
26. Koldamova, R., M. Staufenbiel, and I. Lefterov. 2005. Lack of ABCA1 considerably decreased brain apoE level and increases amyloid deposition in APP23 mice. J. Biol. Chem. 280: 43224-43235. (Pubitemid 43049289)
27. Wahrle, S. E., H. Jiang, M. Parsadanian, J. Kim, A. Li, A. Knoten, S. Jain, V. Hirsch-Reinshagen, C. L. Wellington, K. R. Bales, et al. 2008. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J. Clin. Invest. 118: 671-682. (Pubitemid 351206556)
28. Jiang, Q., C. Y. Lee, S. Mandrekar, B. Wilkinson, P. Cramer, N. Zelcer, K. Mann, B. Lamb, T. M. Willson, J. L. Collins, et al. 2008. ApoE promotes the proteolytic degradation of Abeta. Neuron. 58: 681-693. (Pubitemid 351778466)
29. Janowski, B. A., P. J. Willy, T. R. Devi, J. R. Falck, and D. J. Mangelsdorf. 1996. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 383: 728-731. (Pubitemid 26360651)
30. Lehmann, J. M., S. A. Kliewer, L. B. Moore, T. A. Smith-Oliver, S. S. Sundseth, D. A. Winegar, D. E. Blanchard, T. A. Spencer, and T. M. Wilson. 1997. Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway. J. Biol. Chem. 272: 3137-3140. (Pubitemid 27066798)
31. Beaven, S. W., and P. Tontonoz. 2006. Nuclear receptors in lipid metabolism: targeting the heart of dyslipidemia. Annu. Rev. Med. 57: 313-329. (Pubitemid 43261994)
32. Kalaany, N. Y., and D. J. Mangelsdorf. 2006. LXRS and FXR: the yin and yang of cholesterol and fat metabolism. Annu. Rev. Physiol. 68: 159-191.
33. Willy, P. J., K. Umesono, E. S. Ong, R. M. Evans, R. A. Heyman, and D. J. Mangelsdorf. 1995. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev. 9: 1033-1045.
34. Jamroz-Wisniewska, A., G. Wojcicka, K. Horoszewicz, and J. Beltowski. 2007. Liver X receptors (LXRs). Part II: non-lipid effects, role in pathology, and therapeutic implications. Postepy Hig. Med. Dosw. (Online). 61: 760-785.
35. Wojcicka, G., A. Jamroz-Wisniewska, K. Horoszewicz, and J. Beltowski. 2007. Liver X receptors (LXRs). Part 1: structure, fuction, regulation of activity, and role in lipid metabolism. Postepy Hig. Med. Dosw. (Online). 61: 736-759.
36. Zelcer, N., and P. Tontonoz. 2006. Liver X receptors as integrators of metabolic and inflammatory signaling. J. Clin. Invest. 116: 607-614. (Pubitemid 43326865)
37. Mahley, R. W., and S. C. Rall, Jr. 2000. Apolipoprotein E: far more than a lipid transport protein. Annu. Rev. Genomics Hum. Genet. 1: 507-537.
38. Zelcer, N., N. Khanlou, R. Clare, Q. Jiang, E. G. Reed-Geaghan, G. E. Landreth, H. V. Vinters, and P. Tontonoz. 2007. Attenuation of neuroinflammation and Alzheimer's disease pathology by liver x receptors. Proc. Natl. Acad. Sci. USA. 104: 10601-10606. (Pubitemid 47185711)
39. Koldamova, R. P., I. M. Lefterov, M. Staufenbiel, D. Wolfe, S. Huang, J. C. Glorioso, M. Walter, M. G. Roth, and J. S. Lazo. 2005. The liver X receptor ligand TO901317 decreases amyloid á production in vitro and in a mouse model of Alzheimer's disease. J. Biol. Chem. 280: 4079-4088. (Pubitemid 40288571)
40. Riddell, D. R., H. Zhou, T. A. Comery, E. Kouranova, C. F. Lo, H. K. Warwick, R. H. Ring, Y. Kirksey, S. Aschmies, J. Xu, et al. 2007. The LXR agonist TO901317 selectively lowers hippocampal Abeta42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 34: 621-628. (Pubitemid 46483091)
41. Donkin, J. J., S. Stukas, V. Hirsch-Reinshagen, D. Namjoshi, A. Wilkinson, S. May, J. Chan, J. Fan, J. Collins, and C. L. Wellington. 2010. ATP-binding cassette transporter A1 mediates the beneficial effects of the liver-X-receptor agonist GW3965 on object recognition memory and amyloid burden in APP/PS1 mice. J. Biol. Chem. 285: 34144-34154.
42. Fitz, N. F., A. Cronican, T. Pham, A. Fogg, A. H. Fauq, R. Chapman, I. Lefterov, and R. Koldamova. 2010. Liver X receptor agonist treatment ameliorates amyloid pathology and memory deficits caused by high-fat diet in APP23 mice. J. Neurosci. 30: 6862-6872.
43. Groot, P. H., N. J. Pearce, J. W. Yates, C. Stocker, C. Sauermelch, C. P. Doe, R. N. Willette, A. Olzinskiki, T. Peters, D. d'Epagnier, et al. 2005. Synthetic LXR agonists increase LDL in CETP species. J. Lipid Res. 46: 2182-2191. (Pubitemid 41377470)
44. Kim, W. K., V. Meliton, K. W. Park, C. Hong, P. Tontonoz, P. Niewiadomski, J. A. Waschek, S. Tetradis, and F. Parhami. 2009. Negative regulation of Hedgehog signaling by liver X receptors. Mol. Endocrinol. 23: 1532-1543.
45. Morikawa, M., J. D. Fryer, P. M. Sullivan, E. A. Christopher, S. E. Wahrle, R. B. DeMattos, M. A. O'Dell, A. M. Fagan, H. A. Lashuel, T. Walz, et al. 2005. Production and characterization of astrocytederived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-beta. Neurobiol. Dis. 19: 66-76. (Pubitemid 40544724)
46. Fan, J., S. Stukas, C. Wong, J. Chan, S. May, N. DeValle, V. Hirsch-Reinshagen, A. Wilkinson, M. N. Oda, and C. L. Wellington. 2011. An ABCA1-independent pathway for recycling a poorly lipidated 8.1 nm apolipoprotein E particle from glia. J. Lipid Res. 52: 1605-1616.
47. Brinton, R. D., R. F. Thompson, M. R. Foy, M. Baudry, J. Wang, C. E. Finch, T. E. Morgan, C. J. Pike, W. J. Mack, F. Z. Stanczyk, et al. 2008. Progesterone receptors: form and function in brain. Front. Neuroendocrinol. 29: 313-339.
48. Nathan, B. P., A. G. Barsukova, F. Shen, M. McAsey, and R. G. Struble. 2004. Estrogen facilitates neurite extension via apolipoprotein E in cultured adult mouse cortical neurons. Endocrinology. 145: 3065-3073. (Pubitemid 38829971)
49. Schindler, A. E., C. Campagnoli, R. Druckmann, J. Huber, J. R. Pasqualini, K. W. Schweppe, and J. H. Thijssen. 2008. Classification and pharmacology of progestins. Maturitas. 61: 171-180.
50. Fazio, G., F. Ferrara, G. Barbaro, G. Alessandro, G. Ferrro, G. Novo, and S. Novo. 2010. Protrhombotic effects of contraceptives. Curr. Pharm. Des. 16: 3490-3496.
51. Fotherby, K. 1989. Oral contraceptives and lipids. BMJ. 298: 1049-1050.
52. Teichmann, A. T., P. Cremer, H. Wieland, W. Kuhn, and D. Seidel. 1988. Lipid metabolic changes during hormonal treatment of endometriosis. Maturitas. 10: 27-33.
53. Radberg, T., A. Gustafson, A. Skryten, and K. Karlsson. 1982. Oral contraception in diabetic women. A cross-over study on serum and high density lipoprotein (HDL) lipids and diabetes control during progestogen and combined estrogen/progestogen contraception. Horm. Metab. Res. 14: 61-65. (Pubitemid 12166838)
54. Huovinen, K., M. J. Tikkanen, S. Varonen, M. L. Wilska, T. Westermarck, and H. Vesterinen. 1990. The effect of peroral lynestrenol on serum lipids and lipoproteins in therapeutic amenorrhea of mentally retarded women. Acta Obstet. Gynecol. Scand. 69: 35-40. (Pubitemid 20155757)
55. Graff-Iversen, S., and S. Tonstad. 2002. Use of progestogen-only contraceptives/medications and lipid parameters in women age 40 to 42 years: results of a population-based cross-sectional Norwegian Survey. Contraception. 66: 7-13. (Pubitemid 34880199)
56. Abildayeva, K., P. J. Jansen, V. Hirsch-Reinshagen, V. W. Bloks, A. H. Bakker, F. C. Ramaekers, J. de Vente, A. K. Groen, C. L. Wellington, F. Kuipers, et al. 2006. 24(S)-hydroxycholesterol participates in a liver X receptor-controlled pathway in astrocytes that regulates apolipoprotein E-mediated cholesterol efflux. J. Biol. Chem. 281: 12799-12808. (Pubitemid 43855372)
57. Sayeed, I., and D. H. Stein. 2009. Progesterone as a neuroprotective factor in traumatic brain injury. Prog. Brain Res. 175: 219-237.
58. Stein, D. G., and S. W. Hoffman. 2003. Estrogen and progesterone as neuroprotective agents in the treatment of acute brain injuries. Pediatr. Rehabil. 6: 13-22. (Pubitemid 36626716)
59. Stein, D. G. 2001. Brain damage, sex hormones and recovery: a new role for progesterone and estrogen? Trends Neurosci. 24: 386-391. (Pubitemid 32938541)
60. Wright, D. W., A. L. Kellermann, V. S. Hertzberg, P. L. Clark, M. Frankel, F. C. Goldstein, J. P. Salomone, L. L. Dent, O. A. Harris, D. S. Ander, et al. 2007. ProTECT: a randomized clinical trial of progesterone for acute traumatic brain injury. Ann. Emerg. Med. 49: 391-402.
61. Zhu, Y., J. Bond, and P. Thomas. 2003. Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor. Proc. Natl. Acad. Sci. USA. 100: 2237-2242. (Pubitemid 36297483)
62. Zhu, Y., C. D. Rice, Y. Pang, M. Pace, and P. Thomas. 2003. Cloning, expression, and characterization of a membrane progestin receptor and evidence it is an intermediary in meiotic maturation of fish oocytes. Proc. Natl. Acad. Sci. USA. 100: 2231-2236. (Pubitemid 36297482)
63. Nilsen, J., and R. D. Brinton. 2002. Impact of progestins on estrogen-induced neuroprotection: synergy by progesterone and 19-norprogesterone and antagonism by medroxyprogesterone acetate. Endocrinology. 143: 205-212. (Pubitemid 34056421)
64. Nilsen, J., and R. D. Brinton. 2003. Divergent impact of progesterone and medroxyprogesterone acetate (Provera) on nuclear mitogen-activated protein kinase signaling. Proc. Natl. Acad. Sci. USA. 100: 10506-10511. (Pubitemid 37071908)
65. Singh, M. 2001. Ovarian hormones elicit phosphorylation of Akt and extracellular-signal regulated kinase in explants of the cerebral cortex. Endocrine. 14: 407-415. (Pubitemid 32547825)
66. Duan, H., D. Gu, and T. Mazzone. 2000. Sterols and inhibitors of sterol transport modulate the degradation and secretion of macrophage apoE: requirement for the C-terminal domain. Biochim. Biophys. Acta. 1484: 142-150. (Pubitemid 30175964)
67. Nathan, B. P., S. Bellosta, D. A. Sanan, K. H. Weisgraber, R. W. Mahley, and R. E. Pitas. 1994. Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science. 264: 850-852. (Pubitemid 24193454)
68. Holtzman, D. M., R. E. Pitas, J. Kilbridge, B. Nathan, R. W. Mahley, G. Bu, and A. L. Schwartz. 1995. Low density lipoprotein receptorrelated protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc. Natl. Acad. Sci. USA. 92: 9480-9484.
69. Hayashi, H., R. B. Campenot, D. E. Vance, and J. E. Vance. 2004. Glial lipoproteins stimulate axon growth of central nervous system neurons in compartmented cultures. J. Biol. Chem. 279: 14009-14015. (Pubitemid 38468935)
70. Mauch, D. H., K. Nagler, S. Schumacher, C. Goritz, E. C. Muller, A. Otto, and F. W. Pfrieger. 2001. CNS synaptogenesis promoted by glia-derived cholesterol. Science. 294: 1354-1357. (Pubitemid 33063104)
71. Struble, R. G., E. R. Rosario, M. L. Kircher, S. M. Ludwig, P. J. McAdamis, K. Watabe, M. E. McAsey, C. Cady, and B. P. Nathan. 2003. Regionally specific modulation of brain apolipoprotein E in the mouse during the estrous cycle and by exogenous 17beta estradiol. Exp. Neurol. 183: 638-644. (Pubitemid 37205106)
72. Levin-Allerhand, J., B. S. McEwen, C. E. Lominska, D. B. Lubahn, K. S. Korach, and J. D. Smith. 2001. Brain region-specific upregulation of mouse apolipoprotein E by pharmacological estrogen treatments. J. Neurochem. 79: 796-803. (Pubitemid 33086517)
73. McAsey, M. E., C. Cady, L. M. Jackson, M. Li, S. Randall, B. P. Nathan, and R. G. Struble. 2006. Time course of response to estradiol replacement in ovariectomized mice: brain apolipoprotein E and synaptophysin transiently increase and glial fibrillary acidic protein is suppressed. Exp. Neurol. 197: 197-205. (Pubitemid 41817233)
74. Stone, D. J., I. Rozovsky, T. E. Morgan, C. P. Anderson, H. Hajian, and C. E. Finch. 1997. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro. Exp. Neurol. 143: 313-318. (Pubitemid 27148235)
75. Rozovsky, I., S. Hoving, C. P. Anderson, J. O'Callaghan, and C. E. Finch. 2002. Equine estrogens induce apolipoprotein E and glial fibrillary acidic protein in mixed glial cultures. Neurosci. Lett. 323: 191-194. (Pubitemid 34311909)